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Background: Microtubule stabilizers suppress microtubule dynamics and, at the lowest antiproliferative
concentrations, disrupt the function of mitotic spindles, leading to mitotic arrest and apoptosis. At slightly higher
concentrations, these agents cause the formation of multiple mitotic asters with distinct morphologies elicited by
different microtubule stabilizers.
Results: We tested the hypothesis that two classes of microtubule stabilizing drugs, the taxanes and the
taccalonolides, cause the formation of distinct aster structures due, in part, to differential effects on microtubule
dynamics. Paclitaxel and the taccalonolides suppressed the dynamics of microtubules formed from purified tubulin
as well as in live cells. Both agents suppressed microtubule dynamic instability, with the taccalonolides having a
more pronounced inhibition of microtubule catastrophe, suggesting that they stabilize the plus ends of
microtubules more effectively than paclitaxel. Live cell microscopy was also used to evaluate the formation and
resolution of asters after drug treatment. While each drug had similar effects on initial formation, substantial
differences were observed in aster resolution. Paclitaxel-induced asters often coalesced over time resulting in fewer,
larger asters whereas numerous compact asters persisted once they were formed in the presence of the taccalonolides.
Conclusions: We conclude that the increased resistance of microtubule plus ends to catastrophe may play a role
in the observed inability of taccalonolide-induced asters to coalesce during mitosis, giving rise to the distinct
morphologies observed after exposure to these agents.
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While microtubule targeting agents are among the most
effective therapies used in cancer treatment, little is known
about their mechanisms of action downstream of inhibit-
ing microtubule dynamics. One confounding issue is that
microtubule stabilizers, including paclitaxel, have diverse
cellular effects depending on the concentrations used. In
cell culture, low concentrations of paclitaxel (5–10 nM)
are sufficient to slow microtubule dynamics, resulting in
an extended mitotic delay that cells can eventually exit,
albeit often with misaligned chromosomes [1]. These* Correspondence: risingera@uthscsa.edu
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unless otherwise stated.chromosomal defects can lead to cell death following
mitotic slippage or aberrant division. Higher concentra-
tions of paclitaxel (10 to 500 nM) cause a concentration-
dependent increase in the duration of mitotic arrest [2]
and the formation of abnormal mitotic spindles or asters,
some of which are not nucleated by a centrosome. These
multiple asters prevent normal mitosis and lead to apop-
tosis during mitosis or shortly after mitotic exit [3]. Inter-
estingly, substantially higher, micromolar concentrations
of paclitaxel are required to cause bundling of interphase
microtubules, which is the most recognizable phenotype
associated with this class of drugs [4,5].
Recent studies have shown that paclitaxel exhibits these
same concentration dependent effects in vivo when visual-
ized by intravital microscopy [6]. A sub-therapeutic dose
of 1.2 mg/kg extended the duration of mitosis in dividing
tumor cells. These cells formed bipolar spindles, oftenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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completed mitosis. However, slightly higher, antitumor
concentrations of paclitaxel caused dividing tumor cells to
arrest in mitosis, often with multiple asters [6]. Although
recent studies clearly indicated that the antitumor actions
of microtubule targeted agents also involved their effects
on interphase cells [7,8], the finding that the formation
of multiple microtubule asters is closely correlated with
effective antitumor doses of paclitaxel suggested that a
more detailed analysis of this process may inform the anti-
tumor mechanisms of microtubule stabilizers, including
paclitaxel.
Taccalonolides A and E, the most prevalent taccalono-
lides isolated from plants of the genus Tacca, cause micro-
tubule bundling with short thick tufts of microtubules that
appear quite different from paclitaxel-induced interphase
microtubule bundles [4,9]. These taccalonolides are also
distinct from paclitaxel because they circumvent multiple
mechanisms of drug resistance, including P-glycoprotein
mediated resistance both in vitro and in vivo [9,10] as well
as mutations in the taxane binding site [9] and in cells ex-
pressing βIII tubulin [10]. At the cellular level, taccalono-
lide A is highly persistent following short periods of
exposure to the drug, an effect that is different from most
microtubule stabilizers [4]. While taccalonolides A and E
cause dramatic microtubule stabilization in cells and have
antitumor effects in vivo, no direct interaction with micro-
tubules was observed, possibly because these agents are
significantly less potent than other microtubule stabilizers
[11]. Recently, potent taccalonolides have been isolated
and generated by semi-synthesis [12]. The taccalonolides
AF and AJ differ from taccalonolide A and B by the in-
corporation of a C22,C23 epoxide moiety. They have
potencies in the range of other microtubule stabilizers, in-
cluding paclitaxel, and demonstrate for the first time the
ability of a taccalonolide to interact directly with tubulin/
microtubules through a covalent interaction [13]. Cellular
data suggest that these potent taccalonolides have the
same cellular properties as taccalonolide A, including
strong persistence, the propensity to cause microtubule
bundling at low antiproliferative concentrations and their
effects on cellular signaling and centrosomal separation,
which differ from either paclitaxel or laulimalide [4,14].
Therefore, the epoxidation of C22,23 appears to dramatic-
ally increase the potency of the taccalonolides in biochem-
ical and cellular assays while retaining the mechanisms of
action of less potent taccalonolides.
Microtubule stabilizers, including each of the taccalono-
lides, cause the formation of abnormal mitotic cells with
multiple microtubule asters and cause the mitotic arrest
and death of cancer cells [9]. However, the structures of
the asters formed by the taccalonolides are markedly dif-
ferent from those induced by members of the two major
classes of microtubule stabilizers, paclitaxel or laulimalide[14]. At concentrations that cause mitotic arrest, paclitaxel
often results in the formation of one diffuse aster with two
smaller punctate asters. In contrast, treatment with tacca-
lonolides causes the appearance of much more numerous,
compact asters [9,14].
The goal of this study was to compare the effects of pac-
litaxel and taccalonolide AJ on parameters of dynamic in-
stability, both in biochemical preparations and in live cells.
We hypothesized that the different effects of microtubule
stabilizers on microtubule dynamics might play a role in
the formation of distinct microtubule asters. Our results
show that the distinct ability of the taccalonolides to in-
hibit microtubule shortening and catastrophe might par-
tially explain the inability of multiple microtubule asters to
coalesce, giving rise to the distinct mitotic microtubule
morphology that has been observed for this class of drugs.Results
Effects of taccalonolide AJ and paclitaxel on the dynamic
instability of purified tubulin
The effects of the taccalonolides on multiple parameters
of dynamic instability were measured at the plus ends of
steady-state microtubules made from phosphocellulose-
purified tubulin seeded from axonemes and compared to
the effects caused by paclitaxel. For these studies the
semi-synthetic taccalonolide AJ was used because it has
been shown to stimulate microtubule polymerization in
biochemical assays [12].
Similar to the effects of other microtubule stabilizing
drugs, taccalonolide AJ suppressed microtubule dynamics
at concentrations sub-stoichiometric to tubulin (Table 1).
Taccalonolide AJ had no significant effect on the plus-end
growth rate; however, it suppressed the shortening rate in
a concentration-dependent manner, with inhibition of 38%
and 66% at 1 and 3 μM, respectively. Additionally, taccalo-
nolide AJ inhibited both the catastrophe frequency and
the rescue frequency in a concentration-dependent man-
ner. Specifically, at 1 μM taccalonolide AJ, a 25% reduc-
tion in the catastrophe frequency and a 29% reduction
in the rescue frequency were measured. At 3 μM, more
extensive inhibition of both the catastrophe and rescue
frequencies of 54% and 44%, respectively occurred
(Table 1). Taccalonolide AJ-induced suppression of short-
ening rate, catastrophe and rescue frequencies resulted in
concentration-dependent decreases in growing and short-
ening time with a concomitant increase in the time micro-
tubules were in an attenuated state. Taccalonolide AJ at
1 μM caused a 104% increase in the attenuated state and a
36% decrease in overall dynamicity of the microtubules.
At 3 μM, a 148% increase in attenuation was measured
and the overall dynamicity of microtubules was sup-
pressed by 65%. These results show that taccalonolide
AJ, similar to other microtubule stabilizers, directly
Table 1 Phosphocellulose purified bovine brain microtubules were assembled to steady state in the presence of
taccalonolide AJ, paclitaxel or vehicle and the dynamic instability parameters were determined
Vehicle 1 μM AJ 3 μM AJ 250 nM PTX
Value ± SEM Value ± SEM % Change Value ± SEM % Change Value ± SEM % Change
Growth rate (μm/min) 2.7 ± 0.2 3.1 ± 0.2 +15 3 ± 0.3 +11 2.8 ± 0.2 +4
Shortening rate (μm/min) 11.9 ± 1 7.4 ± 0.6** −38 4 ± 0.5*** −66 5.8 ± 0.4*** −51
Percent time growing 56 34 −39 26 −54 26 −54
Percent time shortening 19 15 −21 12 −37 22 +16
Percent time attenuated 25 51 +104 62 +148 52 +108
Catastrophe frequency (per min) 0.28 ± 0.05 0.21 ± 0.04* −25 0.13 ± 0.03*** −54 0.26 ± 0.04 −7
Rescue frequency (per min) 0.84 ± 0.17 0.60 ± 0.15 −29 0.47 ± 0.15* −44 0.30 ± 0.09** −64
Dynamicity (μm/min) 2.73 1.74 −36 0.95 −65 1.63 −40
Approximately 25 microtubules were measured for each condition.
*P<0.05; **P < 0.01; ***P < 0.001, as determined with a Student’s t-test.
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concentration-dependent manner.
The effects of taccalonolide AJ on suppression of most
parameters of microtubule dynamic instability occurred in
a manner similar to paclitaxel, albeit less potently. The
same degree of dynamicity inhibition (−36% vs. -40%) was
induced by 250 nM paclitaxel and 1 μM taccalonolide AJ,
respectively. Paclitaxel and taccalonolide AJ both sup-
pressed the microtubule plus-end shortening rate with
51% inhibition by 250 nM paclitaxel and only 38% in-
hibition by 1 μM taccalonolide AJ (Table 1). The percent
growing time was inhibited by both compounds, but tac-
calonolide AJ also inhibited the percent shortening time
which was slightly increased by paclitaxel. Both drugs
increased the fraction of time that the microtubules
remained in the attenuated state, although paclitaxel was
again more potent because 250 nM paclitaxel increased
the time attenuated by 108% with 1 μM taccalonolide AJ
causing a 104% increase.
Although taccalonolide AJ and paclitaxel exhibited
many of the same effects on microtubule dynamics,
there were major differences observed in the frequency
of catastrophe and rescue. Whereas 250 nM paclitaxel
did not significantly alter the catastrophe frequency,
1 μM taccalonolide AJ suppressed catastrophe frequency
by 25% (Table 1). In contrast, 250 nM paclitaxel caused
a large, 64%, decrease in rescue frequency, while no sig-
nificant effect on this parameter was caused by 1 μM
taccalonolide AJ. At these same concentrations, the two
drugs caused equivalent effects on overall microtubule
dynamicity, preferentially suppressing either the catas-
trophe or rescue frequencies, respectively. The greater
suppression of the catastrophe frequency caused by tac-
calonolide AJ indicated that the microtubules have a
lower propensity to revert to a shrinking state compared
to paclitaxel. In contrast, paclitaxel has a larger effect on
the suppression of rescue frequency and thus a higherpropensity than taccalonolide AJ to inhibit the switch to
microtubule growth.Effects of Taccalonolide AJ and paclitaxel on microtubule
dynamics in live cells
The effects of paclitaxel and taccalonolide AJ on micro-
tubule dynamics in MCF7-EGFP-α-tubulin cells were
also evaluated (Table 2). Taccalonolide AJ and paclitaxel
were found to have nearly identical antiproliferative po-
tencies in this cell line with IC50 values of 37 ± 4.6 nM
and 36 ± 3.8 nM, respectively (data not shown), allowing
for a direct comparison of equal drug concentrations on
microtubule dynamics.
Similar to its effects on purified tubulin, taccalonolide
AJ caused dose-dependent suppression of microtubule
dynamics over a range of 25 – 100 nM (Table 2). The
most dramatic effects of taccalonolide AJ were a marked
suppression of both the shortening rate and the catas-
trophe frequency, which were suppressed at 50 nM by
39% and 33%, respectively, and were not suppressed fur-
ther at higher concentrations. These changes led to de-
creases in overall dynamicity of 25% and 62% at 25 and
50 nM, respectively (Table 2). The almost identical
effects observed at 50 and 100 nM taccalonolide AJ for
all parameters suggested that drug binding or uptake
may be saturated at 50 nM over the 4-h time course.
Paclitaxel caused a similar dose-dependent suppression
of shortening rate and catastrophe frequency; however,
higher concentrations of paclitaxel than of taccalonolide
AJ were required to observe comparable effects. For in-
stance, overall dynamicity was decreased 34% by 50 nM
paclitaxel while the same concentration of taccalonolide
AJ caused a 62% decrease (Table 2). An almost identical
decrease in overall dynamicity was observed for 150 nM
paclitaxel versus 50 nM taccalonolide AJ, demonstrating
that taccalonolide AJ is a more potent inhibitor of
Table 2 Suppression of microtubule dynamic instability in MCF7-EGFP-α-tubulin cells incubated with vehicle,
taccalonolide AJ or Paclitaxel























Growth rate (μm/min) 7.5±0.25 7.2±0.3 −5.1 6.9±0.3 −8.50 6.5±0.3 −13.3** 7.2±0.3 −3.9 6.5± 0.3 −13.3**
Shortening rate (μm/min) 13.9±0.9 12.0±0.8 −14.0 8.6±0.4 −38.5*** 9.1±0.9 −34.9*** 12.0±0.7 −13.9 8.0±0.5 −42.5***
Percent Time Growing 35.8 29.2 −18.6 14.9 −58.3 14.9 −58.4 26.0 −27.5 18.2 −49.3
Percent Time Shortening 16.6 13.7 −17.3 9.7 −41.6 9.7 −41.7 11.5 −31.1 7.8 −53.4
Percent Time Attenuated 47.6 57.1 20.1 75.4 59.0 75.4 58.6 62.6 31.6 74.1 55.8
Catastrophe Frequency
(per min)
1.8±0.1 1.6±0.2 −8.9 1.2±0.1 −32.8*** 1.2±0.1 −36.1*** 1.4±0.1 −21.1* 1.3±0.2 −30.0*
Rescue Frequency
(per min)
10.4±0.5 10.5±0.6 0.6 11.6±0.7 11.4 11.0±0.7 5.9 11.2±0.6 7.5 12.8±0.6 22.8**
Dynamicity 5.1 3.8 −25.3 1.9 −62.3 1.9 −62.1 3.3 −34.1 1.9 −62.33
MTs/Cells Counted 40/18 41/13 41/13 31/12 47/14 30/13
% Dynamic MTs 65 51 41 32 54 44
*P < 0.05; **P < 0.01; ***P < 0.001 as determined with a Student’s t-test.
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though the reverse was true with purified tubulin (Tables 1
and 2).
At concentrations of 50 nM taccalonolide AJ and 150
nM paclitaxel, which caused a similar suppression of
overall dynamicity, many of the individual parameters of
dynamic instability were also identical, including growth
and shortening rates and catastrophe frequency (Table 2).
However, one distinct finding was that 150 nM paclitaxel
significantly increased the rescue frequency by 23%,
which was not affected at any concentration of taccalo-
nolide AJ. Together, these data demonstrate that taccalo-
nolide AJ decreases microtubule dynamicity similarly to
paclitaxel, but with notable distinctions in the frequency
of rescue and catastrophe that might impart differences
in their cellular effects.
Differential mitotic microtubule structures formed by the
taccalonolides and paclitaxel
Microtubule targeting agents arrest cancer cells in mitosis
with abnormal mitotic microtubule asters. Distinct micro-
tubule morphologies are induced by different microtubule
stabilizers, particularly paclitaxel and the taccalonolides
[9,14]. We hypothesized that their subtle differences on
the inhibition of microtubule dynamics contribute to the
formation of morphologically distinct mitotic asters. Since
these drugs range in potency, we compared the effects of
the taccalonolides and paclitaxel on spindle formation
at the minimum concentration that caused maximal mi-
totic arrest.
The lowest concentration that caused maximal G2/M ar-
rest of HeLa cells was determined for each drug using flow
cytometry and was found to be 12 nM for paclitaxel, 20
nM for taccalonolide AJ and 5 μM for taccalonolide A.Consistent with prior results, the phenotypes of the mi-
totic asters formed by these drugs were quite different
(Figure 1). In comparison to vehicle-treated cells that con-
tained a normal bipolar spindle (Figure 1), the majority of
paclitaxel-treated cells contained a single large, diffuse
aster that was often accompanied by two smaller, more
punctate asters (Figure 1). In contrast, cells treated with
either taccalonolide A or AJ contained 5–7 asters that
were small, compact and consistent in morphology
(Figure 1).
Mechanisms of aster formation identified by live cell
microscopy
Studies were initiated using high content imaging with
GFP-β-tubulin expressing HeLa cells to identify how
these structurally distinct microtubule asters are formed
in the presence of paclitaxel or the taccalonolides. As in
Figure 1, drugs were added at the minimal concentration
that caused maximal G2/M accumulation: 12 nM pacli-
taxel and 5 μM taccalonolide A. Cells in 60 microscopic
fields per treatment condition were followed at 30 min
intervals over an 8 h period after drug addition. The
number of cells in mitosis and the number of micro-
tubule asters in each cell were counted at each time
point. In vehicle-treated cells, the cells continued to
cycle normally and did not accumulate in mitosis. At the
time of drug addition (0 h), an average of 74 mitotic cells
(range 64–82) was observed for each treatment group
with the vast majority (89–92%) of these mitotic cells
containing normal bipolar spindles (Figure 2). Within
2 h of paclitaxel addition, a slight increase in the number
of mitotic cells was observed, but the percentage of
those with bipolar spindles remained at 90%. The num-
ber of cells in mitosis doubled 3 h after paclitaxel
Figure 1 Mitotic asters induced by paclitaxel or the taccalonolides. The mitotic asters in HeLa cells treated with vehicle, 12 nM paclitaxel,
5 μM taccalonolide A or 20 nM taccalonolide AJ, the minimum concentrations that caused maximum mitotic accumulation, were visualized by
indirect immunofluorescence for β-tubulin (top). DNA was visualized by DAPI staining (middle) and merged images are shown with microtubules
in green and DNA in blue (bottom).
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contained more than two asters (Figure 2A). The num-
ber of mitotic cells continued to increase from 4–8 h
and by 8 h, 14 times as many cells were in mitosis com-
pared to the time of paclitaxel addition. The number
and the percentage of cells containing aberrant micro-
tubule asters also increased and by 8 h, 71% of the
paclitaxel-treated mitotic cells contained more than 2
microtubule asters (Figure 2A).
A similar pattern of accumulation of cells in mitosis
and an increase in the percentage of cells with aberrant
microtubule structures was observed with taccalonolide
A, with the majority of taccalonolide-treated mitotic
cells containing greater than two asters as early as 3 h
after drug addition (Figure 2B). By 4 h, 89% of the
taccalonolide- treated mitotic cells had more than two
asters and the percentage increased to 97% by 8 h. Inter-
estingly, the total number of mitotic cells present after
treatment with either agent was similar through the first
3 h, but at 4, 6 and 8 h after treatment more mitotic
cells were observed with taccalonolide A treatment than
with paclitaxel (Figure 2). While each of the microtubule
stabilizers caused accumulation of cells in mitosis with
multiple asters, both the total number of cells in mitosisand the percentage of cells containing greater than 2
microtubule asters were substantially higher with tacca-
lonolide treatment, suggesting that the mitotic spindle
defects might be more difficult to resolve.
The same images were analyzed as time courses to ob-
serve the formation of mitotic microtubule asters in in-
dividual cells following treatment with either paclitaxel
or taccalonolide A. The initial microtubule morphology
of cells that entered mitosis within 3.5 h after drug
addition was noted and followed over the course of 8 h
in order to monitor for changes in microtubule struc-
tures over time. The fates of cells entering mitosis after
drug addition were divided into four categories: 1) cells
that entered mitosis with a bipolar spindle followed by
cell division, 2) cells that entered mitosis with a bipolar
spindle that persisted without any change in spindle or
cellular morphology during the observed time course, 3)
cells that initially entered mitosis with a bipolar spindle
that transitioned into greater than two asters as time
progressed and 4) cells that contained 3 or more asters
upon entry into mitosis with no indication of passing
through a bipolar spindle intermediate. Representative
pictures of cells in each of these categories are shown
in Figure 3A. The distribution of phenotypes that were
Figure 2 Effects of paclitaxel or taccalonolide A on mitotic
accumulation and aster number. The number of mitotic cells
present at each time after the addition of (A) 12 nM paclitaxel or
(B) 5 μM taccalonolide A to GFP-β-tubulin expressing HeLa cells was
counted. These mitotic cells were classified as containing bipolar
spindles (black) or multiple asters (gray). Cells from 60 microscopic
fields (20x) from 12 individual wells were analyzed for each
condition at each time point.
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calonolide A treatment is presented in Figures 3B and C,
respectively. The total number of cells that entered mi-
tosis during each 30 min interval after drug addition was
largely unchanged over time, indicating that neither drug
had major effects on the rate of mitotic entry.
At the time of drug addition, several cells were in mi-
tosis (time 0). When these cells were followed over the
next 8 h, more than 90% completed cell division and no
differences were noted between those treated with pacli-
taxel or taccalonolide (Figure 3B and C, black bars). As
early as 1.5 h after paclitaxel addition, the percentage of
cells that entered mitosis with bipolar spindles decreased
from 93% to 79%. By 2 h after exposure, less than half(47%) of the cells that had entered mitosis were ob-
served to have completed cell division after forming a bi-
polar spindle (Figure 3B, black bar). After 2.5 h of
paclitaxel treatment, only 2% of the cells that entered
mitosis were able to form a normal bipolar mitotic spin-
dle and complete cell division. With exposure times of
3 h or longer, no cells of this phenotype were observed.
Cells that entered mitosis with a bipolar spindle that
persisted throughout the 8 h total observation period
were detected beginning 2 h after paclitaxel treatment
(Figure 3B, hatched bar). The number of cells exhibiting
this phenotype, 5-8%, remained relatively constant for cells
entering mitosis 2–3.5 after paclitaxel addition. Within 2 h
of paclitaxel treatment, 40% of the cells entering mitosis
contained a bipolar spindle that transitioned into multiple
aberrant asters over time (Figure 3B, gray bars). Addition-
ally, 9% of the cells entered mitosis with multiple asters
without first forming a bipolar spindle (Figure 3B, white
bars). Two to 2.5 h after paclitaxel addition, the number
and percentage of cells that entered mitosis with a bipolar
spindle that then transitioned into multiple asters in-
creased. At later time points fewer cells exhibited this fate
and a concomitant increase in cells that entered mitosis
with multiple asters was observed. The percentage of
paclitaxel-treated cells exhibiting this phenotype plateaued
at 60-62% at later time points (Figure 3B). These results
show that paclitaxel caused the formation of multiple
types of microtubule structures, including bipolar spindles
that were competent for cell division, bipolar spindles that
persisted but were dysfunctional, bipolar spindles that
transitioned into multiple asters and those that contained
more than two asters upon mitotic entry. As time after
drug exposure increased, fewer paclitaxel-cells were able
to form bipolar spindles upon mitotic entry and those that
did form bipolar spindles transitioned to contain multiple
asters. At 3.5 h after paclitaxel addition, the majority of
the cells entered mitosis with multiple asters that persisted
over the remaining period of observation.
Taccalonolide A caused similar effects, with a time-
dependent loss of cells that entered mitosis with functional
bipolar spindles and a concomitant increase in cells that
formed multiple asters after entering mitosis (Figure 3C).
However, the kinetics and magnitude of the changes dif-
fered between cells treated with paclitaxel or taccalonolide
A. The ability of taccalonolide A to induce the formation
of dysfunctional spindles was delayed as compared to pac-
litaxel. At 2 h after taccalonolide A addition, the vast
majority of cells, 75%, formed a bipolar spindle and com-
pleted cell division. In contrast, less than half of paclitaxel-
treated cells treated for 2 h were able to do so. As the time
of taccalonolide A exposure increased, fewer cells were
able to enter mitosis with a bipolar spindle and 3.5 h after
drug addition, no mitotic cells were seen to complete cell
division during the course of observation.
Figure 3 Aster formation following the addition of paclitaxel or taccalonolide A. GFP-β-tubulin expressing HeLa cells were treated with 12
nM paclitaxel or 5 μM taccalonolide A. Every cell that entered mitosis within 3.5 h after drug addition was followed until 8 h after drug addition
and placed in one of 4 categories. (A) Representative images of the 4 categories of cells entering mitosis: bipolar spindle formation followed by
cell division, bipolar spindle formation that persisted without completion of mitosis, bipolar spindle that resolved into multiple asters or formation
of multiple asters immediately upon mitotic entry. Each image represents approximately 40 μm. The category of cells entering mitosis at the
indicated time points following (B) paclitaxel or (C) taccalonolide A addition are shown. Cells in 60 individual microscopic fields from 12 separate
wells were analyzed for each condition at each time point. (D) Effects of NuMA depletion on taccalonolide A-induced asters. Microtubules were
visualized by indirect immunofluorescence 4 h after the addition of 5 μM taccalonolide A in control (GADPH siRNA) and NuMA-depleted (NuMA
siRNA) HeLa cells (right). DNA was visualized by DAPI staining (left).
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and percentage of cells that entered mitosis with bipolar
spindles that progressed to multiple asters increased
0–2.5 h after taccalonolide A addition and subsequently
decreased at later time points. The number of cells con-
taining multiple asters when they entered mitosis began
to increase 2.5 h after drug addition and 90% of cells
that entered mitosis 3.5 h after taccalonolide A addition
had this phenotype. Interestingly, at the same time
point only 63% of paclitaxel-treated cells exhibited mul-
tiple asters upon mitotic entry. Later time points, i.e.,
4–6 h after drug addition, were evaluated and no furtherchanges in spindle/aster morphologies were detected in
either the paclitaxel- or taccalonolide A-treated cells
entering mitosis, suggesting the morphology upon mi-
totic entry had reached a steady state within 3.5 h of the
addition of either drug. These data delineate similarities
between the two drugs in their ability to form aberrant
asters through a common set of phenotypically similar
intermediate spindle morphologies. However, it also
highlights their differences; including the fact that pacli-
taxel inhibits cell division at earlier timepoints while the
multiple aster phenotype is observed to a greater extent
after taccalonolide A treatment.
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During evaluation of the time course images of mitotic
aster formation, it was evident that several of the cells
which contained multiple asters upon mitotic entry
passed through an intermediate stage where the micro-
tubules localized to cell periphery as well as internal
areas that may overlap with nuclear material (Figure 3A,
bottom row; Additional file 1: Figure S1). To gain higher
temporal resolution of this process, images of taccalono-
lide A-treated cells were acquired every minute for 1 h
starting 3 h after drug addition. Multiple microtubule as-
ters were indeed found to be first nucleated at the cor-
tical membrane in every cell that entered mitosis with
multiple asters (data not shown), indicating that this is a
common intermediate stage in the formation of these
aberrant mitotic asters. Representative images depicting
the localization of microtubules to the cell periphery and
around DAPI stained nuclear material 4 h after taccalono-
lide A-treatment are shown in Additional file 1: Figure S1.
It has been previously shown that high concentrations of
paclitaxel also cause a redistribution of microtubules to
the cell cortex where they co-localize with the microtubule
crosslinking protein NuMA [15].
The role and requirement for NuMA in the formation of
taccalonolide-induced aberrant mitotic asters was investi-
gated. An 80% depletion of NuMA protein levels by siRNA
did not affect mitotic entry in the presence or absence of
taccalonolide A as determined by chromosome condensa-
tion and the RhoA-mediated rounding up of cells that oc-
curs prior to mitotic entry (Figure 3D). Evaluation of
mitotic entry as defined by these criteria indicated mitotic
indices of 39% and 32% in GADPH-depleted control cells
and NuMA-depleted cells, respectively. The morphology
of mitotic asters in taccalonolide A-treated mitotic cells de-
pleted of NuMA was notably different from that observed
in cells expressing normal levels of NuMA. While the early
taccalonolide A-induced mitotic phenotype with microtu-
bules congregated around the cellular cortex was readily
observed in NuMA-depleted cells, there was a noticeable
decrease in mitotic cells with mature, fully formed asters
(Figure 3D). Quantification of spindle phenotypes indicated
that NuMA depletion reduced the percentage of mitotic
cells containing mature, punctate asters from 25% to 12%,
with a concomitant increase in mitotic cells with cortically
localized microtubules. These data are consistent with pre-
vious reports describing the localization of microtubules to
the cell cortex upon mitotic entry in the presence of micro-
tubule targeting agents as a passive process [15] and sug-
gest a role for NuMA in taccalonolide A-induced aster
formation from these cortically organized microtubules.
Differential aster resolution identified by live cell microscopy
The overriding similarities in aster formation for cells en-
tering mitosis in the presence of paclitaxel or taccalonolideA were somewhat surprising given the very distinct aster
morphologies observed when cells had been treated for
18 h with either drug (Figure 1). To further understand
these steady-state phenotypic differences, changes in the
aster morphologies of cells containing multiple asters were
monitored after their initial formation. Three distinct phe-
notypes were observed over time as shown in Figure 4A: 1)
an increase in the total number of asters (yellow), 2) a
decrease in the total number of asters (green) or 3) no
significant change in the number of asters (red). When
these phenotypes were quantified, approximately 80% of
taccalonolide A-treated cells that contained multiple as-
ters 5 h after drug addition showed no gross changes in
morphology 3 h later (Figure 4B). In contrast, almost
half of paclitaxel-treated cells consolidated their asters
over the same time period, resulting in fewer, larger asters.
The consolidation of asters was occasionally able to re-
solve to the extent that cell division occurred within the
observed time frame. This consolidation of asters was not
uncommon in paclitaxel-treated cells, but rarely occurred
with taccalonolide A treatment. These results are con-
sistent with the differences observed in the steady-state
aster morphologies after treatment with each microtubule
stabilizer (Figure 1) and with the fact that fewer cells are
observed in mitosis after paclitaxel treatment (Figure 2).
These experiments were reproduced with the more potent
taccalonolides AF and AJ and the results were consistent
to those obtained with taccalonolide A, particularly with
regard to the inability of asters to coalesce (data not
shown), suggesting that this is a common mechanism of
the taccalonolides.
Discussion
Paclitaxel and the taccalonolides, drugs representing two
classes of microtubule stabilizers, were compared for their
effects on microtubule dynamic instability and mitotic
aster formation. Although the steady state aster morph-
ologies of cells treated with the taccalonolides or paclitaxel
are quite distinct (Figure 1), time lapse microscopy indi-
cated that the microtubule structures formed at the onset
of mitosis are essentially identical (Figure 3). These two
microtubule stabilizers did not affect the rate of mitotic
entry and cells treated with either drug showed a similar
evolution of three distinct mitotic fates. At 0–2 h after
drug addition, cells entering mitosis continued to form a
seemingly normal bipolar spindle and to complete cellular
division. Once cells had been exposed to either drug for
2–3 h, the majority of cells formed bipolar spindles upon
mitotic entry that either persisted in mitosis or transi-
tioned into multiple asters. Finally, the majority of cells
that entered mitosis more than 3 h after addition of either
drug formed multiple asters after initially nucleating mi-
crotubules near the cell periphery. Interestingly, although
NuMA depletion did not appear to affect the ability of
Figure 4 Resolution of drug induced asters. The resolution of the multiple asters formed in GFP-β-tubulin expressing HeLa cells after the
addition of 12 nM paclitaxel or 5 μM taccalonolide A were evaluated 5–8 h after drug addition. (A) A representative microscope field showing
mitotic cells that undergo: 1) a decrease in aster number (green circle), 2) increase in aster number (yellow circle) or 3) no change in number of
asters (red circle) are indicated. (B) Percentage of mitotic cells that undergo each phenotype or successfully divide during the time period. 100
cells were followed over time for each condition.
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the cell periphery (which appears to be an early step in
multiple aster formation), it inhibited the ability of these
cortically localized microtubules to form mature asters
(Figure 3D). This finding is consistent with the ability of
NuMA to nucleate microtubule asters even in cell free
systems [16].
Although the initial process of aster formation in re-
sponse to treatment with the two drugs is similar, the ef-
fects on the fate of these mitotic asters are distinct. The
multiple asters formed in the presence of paclitaxel tend
to merge together over time to form larger, more diffuse
asters. This tendency for paclitaxel-treated cells to consoli-
date multiple asters is similar to previous study results
showing that cells containing supernumerary centrosomes
also consolidate them to correct the defect and form a bi-
polar spindle [17]. Although the multiple asters formed
during treatment with microtubule stabilizers are not
a result of centrosomal over duplication [14], a similar
mechanism might be responsible for consolidating these
non-centrosomal asters into structures that more closely
resemble a bipolar spindle. The fact that paclitaxel-treated
cells are able to consolidate multiple small asters into
fewer, larger structures suggests that aster coalescence
does not require the presence of centrosomal proteins.In contrast to the aster consolidation that occurs with
paclitaxel, asters formed in the presence of the tacca-
lonolides are more static. In the vast majority of
taccalonolide-treated mitotic cells, no changes in aster
number and/or morphology were observed after their
initial formation (Figure 4). This finding is intriguing in
light of the observation that the taccalonolides and pac-
litaxel have subtle differences in their ability to inhibit
parameters of microtubule dynamic instability in both
purified tubulin preparations or in live cells (Tables 1, 2).
While taccalonolide AJ suppressed catastrophe fre-
quency in both assays, paclitaxel only did so in live cells
where there are numerous other microtubule associated
proteins that also affect microtubule dynamics (Table 2).
We hypothesize that the intrinsic ability of the taccalono-
lides to profoundly suppress microtubule catastrophe in
purified tubulin preparations may play a role in the find-
ing that they prevent microtubule asters from coalescing
into fewer, larger structures in mitotic cells. Additionally,
it has recently been reported that the taccalonolides im-
part a dramatic inter-protofilament stability to microtu-
bules by covalently binding to the 212–230 peptide of
β-tubulin [13]. This binding may also indirectly affect
microtubule dynamics in cells by altering their association
with microtubule associated proteins, including molecular
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modifications.
The finding that taccalonolide AJ is less potent than
paclitaxel in its ability to impact the dynamics of purified
tubulin but more potent in its ability to do so in live
cells is also consistent with our previous observations
that the cellular effects of the taccalonolides are more
persistent than paclitaxel, which may relate to their abil-
ity to be concentrated and/or retained in cells. This has
been observed for other microtubule targeted agents,
including paclitaxel, which are concentrated across the
cellular membrane and to generate intracellular drug
concentrations that are much higher than the surround-
ing medium [18-22]. We hypothesize that the covalent
binding of the taccalonolides to tubulin/microtubules
[13] also allows them to be retained and concentrated in
the cell, which may allow for a higher local concentra-
tion that is sufficient to stabilize microtubules. It will be
interesting to test this hypothesis with the generation of
radiolabeled material. Together, these observations sug-
gest that the taccalonolides impart increased stability to
intact microtubules, as compared to paclitaxel, which
may make them less prone to reorganization.
In our analysis of aster formation in the presence of
microtubule stabilizers, the minimum concentrations of
drugs that caused maximal mitotic arrest were used to
directly compare their effects on mitotic entry (Figure 1).
Another study analyzed aster formation at concentra-
tions of paclitaxel up to three orders of magnitude
higher than those that cause mitotic arrest [15]. In this
earlier study, the formation of asters followed an identi-
cal mechanism; microtubules were initially localized to
the cell cortex upon entry into mitosis after which they
formed multiple asters. In contrast to our study using 12
nM paclitaxel, the asters that formed in the presence of
10 μM paclitaxel did not coalesce over time, which was
similar to the effects observed with antiproliferative con-
centrations of the taccalonolides. This finding demon-
strates that high concentrations of paclitaxel, several times
higher than those which cause mitotic arrest, can lead to
the formation of asters similar to those formed by the tac-
calonolides at low, antiproliferative concentrations. In-
deed, we also observed that at concentrations of paclitaxel
10 – 50 times higher than those that cause mitotic arrest,
asters began to have a lower propensity to coalesce. There-
fore, it appears that microtubule stabilization is correlated
with the concentration of drug, which is consistent with
the high level of stabilization observed with a covalently
bound drug such as taccalonolide AJ. However, it is also
possible there is some mechanistic difference between
drugs as even extremely high concentrations of paclitaxel
do not cause the dramatic inhibition of aster consolidation
observed with antiproliferative concentrations of the tac-
calonolides (unpublished observation).Conclusions
Together, these data strongly suggest that the taccalono-
lides have a distinct ability to impart microtubule stabil-
ity by directly inhibiting microtubule catastrophe, which
may explain some of the observed effects of this class of
microtubule stabilizers, including their ability to inhibit




Taccalonolide A was isolated from plants of the genus
Tacca as previously described [10]. The taccalonolide A
used in this study is identical to the material used in several
previous cellular based studies [4,10,23]. Taccalonolide AJ
was generated by semi-synthesis as described previously
[12]. Paclitaxel was obtained from Sigma (St. Louis, MO).
Ethanol was used as a vehicle for all drugs.
Cell culture
HeLa cells were purchased from American Type Tissue
Culture Collection (Manassas, VA). GFP-β-tubulin ex-
pressing HeLa cells were kindly provided by Dr. Paul
Chang of MIT. Cells were grown in Basal Media Eagle
(Invitrogen; Carlsbad, CA) supplemented with 10% fetal
bovine serum (Hyclone; Logan, UT) and 50 μg/ml genta-
micin sulfate (Invitrogen). MCF7 breast carcinoma cells,
stably expressing enhanced green fluorescence protein
conjugated to α-tubulin (MCF7-EGFP-α-tubulin) [24]
were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) (Sigma-Aldrich, St. Louis Missouri) containing
3.7 g/L sodium bicarbonate, 1% non-essential amino acids,
and 1% penicillin-streptomycin, pH 7.2. Cells expressing
EGFP-tubulin were selected by culturing cells in DMEM
supplemented with G418 (0.5 mg/ml) for 2 weeks. Cells
were used within six months of resurrection from liquid
nitrogen.
Microtubule dynamic instability with phosphocellulose
purified tubulin
Effects of taccalonolide AJ or paclitaxel on the dynamic
instability of phosphocellulose purified, MAP-free bovine
brain microtubules were determined using differential
interference contrast microscopy as previously described
[25]. Briefly, tubulin (17 μM) was assembled onto the
ends of sea urchin (Strongylocentrotus purpuratus) axo-
neme seeds with or without drug in PMEM buffer
(87 mM Pipes, 36 mM MES, 1 mM EGTA, 2 mM
MgCl2, pH 6.8) in the presence of 2 mM GTP. Samples
were incubated for 30 min at 35ºC for the microtubules
to reach steady state. Real-time, 10 min-duration videos
of the microtubules were collected using an Olympus
IX71 inverted microscope with a 100× oil immersion ob-
jective (NA = 1.4) at 35ºC . Microtubules were tracked
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(Media Cybernetics, Bethesda, MD) [26]. Dynamic in-
stability parameters were determined as described [27].
At least 25 microtubules were analyzed per condition
and statistical analysis was performed using a Student’s
t-test.Microtubule dynamics in cells
Drugs were added to MCF7-EGFP-α-tubulin cells in 1%
FBS for 4 h after which coverslips were placed in recording
media (10% FBS-DMEM, lacking phenol red and sodium
bicarbonate, but supplemented with 15 mM HEPES,
3.5 g/L glucose, Oxyrase (1:50 dilution), and DL-lactate
(10 mmol/L)). Cells were visualized using a 100× Nikon
Plan Apo objective (N.A. 1.4, oil immersion) at 37°C on a
Nikon Eclipse E800 microscope (Nikon; Tokyo, Japan)
equipped with a CoolSNAP HQ2 camera (Roper Scientific
GmbH, Ottobrunn, Germany). Images were taken at 4-s
intervals for 2.5 min using an exposure time of 600 ms, no
binning, and an 8-bit image auto scale using Metamorph
software (Molecular Devices, Sunnyvale, CA) [28]. Plus
ends of microtubules were tracked using Igor Pro 6.22A:
Microtubule Life History Analysis Package designed by
Dr. Emin Oroudjev (University of California Santa
Barbara, 2010). Dynamic instability parameters were de-
termined as described [28]. A minimum of 30 microtu-
bules were measured from three independent experiments
per condition, and reported as mean ± SEM.High content live cell microscopy
HeLa cells expressing GFP-β-tubulin were grown in
384-well bottom view plates to 80% confluence. Taccalo-
nolides A, AJ or paclitaxel were added to 12 wells at the
minimum concentration that caused maximal G2/M ar-
rest as determined by flow cytometry. Ethanol was added
to an additional 12 wells as a vehicle control. Images
from 5 frames in each of the 12 wells for each condition
were acquired every 30 min for 8 h using the 20× long
working distance objective of the Operetta high content
imaging system (PerkinElmer, Waltham, MA). Mitotic
cells in each frame were identified and the number of
mitotic asters in each cell was counted at each time
point. A total of 60 images were evaluated at each time
point for each treatment condition. The time when indi-
vidual cells entered mitosis was identified using these
images. Entry into mitosis was defined by the clear tran-
sition from an interphase microtubule cytoskeleton to
one containing mitotic spindles or asters between two
consecutively acquired images. Time-lapse movies for
each field were then made from the images to determine
the changes that occurred in the spindle/aster morph-
ology of individual cells over time.Immunofluorescence microscopy and NuMA siRNA
HeLa cells were transfected with NuMA or GADPH
siRNA (Life Technologies, Grand Island, NY) in oligofec-
tamine for 72 h. Taccalonolide A was added to for 4 h after
which cells were immediately fixed and microtubules vi-
sualized by indirect immunofluorescence for β-tubulin
with a Nikon Eclipse 80i fluorescence microscope and
NIS Elements software as previously described [29]. The
distribution of cells in interphase, in mitosis with cortically
localized tubulin, and in mitosis with asters were deter-
mined. A minimum of 800 cells were evaluated for each
treatment condition.
Additional file
Additional file 1: Figure S1. Microtubules localized to the cell
periphery and nuclear region during early aster formation. Microtubules
in HeLa cells treated for 4 h with 5 μM taccalonolide A were visualized
by indirect immunofluorescence for β-tubulin (green). Cells undergoing
early stages of aster formation with microtubules localized to the cell
periphery and near DAPI stained nuclear material (blue) are indicated
with arrows.
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